Novavax, Inc. NVAX
Updated: 17 Jun 2026
No signal published yet
We already track Novavax and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Novavax, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Novavax free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 6, 2026, Novavax reported first-quarter revenue of $140 million and highlighted a new license agreement with Pfizer for its Matrix-M adjuvant. In June 2026, a study published in JAMA Internal Medicine indicated that the company's protein-based COVID-19 vaccine was associated with a significantly lower risk of major cardiovascular events. The company also recently prioritized its C. difficile vaccine candidate for clinical entry as early as 2027.
What Firelda Watch includes for Novavax, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Novavax, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Novavax free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more